[junkie-button url=”https://infomeddnews.com/” style=”grey” size=”medium” type=”round” target=”_blank”] HOME [/junkie-button]

[junkie-alert style=”red”] Johnson & Johnson (NYSE: JNJ) today announced the completion of the divestiture of its Codman Neurosurgery business to Integra LifeSciences Holding Corporation for an approximate value of $1.045 billion, subject to customary adjustments. [/junkie-alert]

The Codman Neurosurgery business offers a portfolio of devices focused on hydrocephalus management, neuro intensive care and cranial surgery, and generated net revenues of approximately $371.5 million in 2016.

Johnson & Johnson remains dedicated to ischemic and hemorrhagic stroke treatment through its newly launched Johnson & Johnson Medical Devices Companies* platform, CERENOVUS**, with a portfolio that includes aneurysm coils, vascular reconstruction devices and other technologies used in the endovascular treatment of cerebral aneurysms and stroke. The CERENOVUS product portfolio has been expanded through the recent acquisitions of Pulsar Vascular Inc., with a specialty in the endovascular treatment of wide-neck bifurcated aneurysms, and Neuravi Limited, offering extensive expertise and knowledge in acute ischemic stroke with its EmboTrap® Revascularization Platform.